Private Sector Involvement

  • Your Selections:

Refine Results

date

Tags

Continued Support Of USAID NTD Program, Collaborative Partnerships Necessary To End NTDs

The Hill: Securing America’s legacy in the fight against neglected tropical diseases Mary Ann Peters, CEO of the Carter Center, former U.S. Ambassador to Bangladesh “…[N]ews rarely captures one of the biggest global health successes to date: our country’s efforts to eliminate neglected tropical diseases (NTDs). The NTD Program is…

Global Health Community Must Engage Private Sector To Create Reproductive Health-Related Corporate Social Responsibility Standards

Global Health NOW: Not Your Father’s Oldsmobile: Engaging Corporations on Reproductive Health David Wofford, vice president of Meridian Group International, Inc. and senior adviser on workplace policies at the Evidence Project “…The global health community needs to ask corporations to do more on reproductive health and rights policy and practice.…

Investors Announce $25M To Improve Access To Water, Sanitation In Latin America

Humanosphere: Investors pour $25 million into better water and sanitation in Latin America Humanosphere journalist Lisa Nikolau discusses the announcement made by the FEMSA Foundation, Coca-Cola Latin America, the Inter-American Development Bank (IDB), and the One Drop Foundation to invest “$25 million into an initiative to improve access to water…

President Trump Should Demand Fair Prices For Zika Vaccine From Sanofi

New York Times: Bernie Sanders: Trump Should Avoid a Bad Zika Deal Bernie Sanders, independent senator from Vermont “…[The Trump] administration, through the Army, is on the brink of making a bad deal, giving a French pharmaceutical company, Sanofi, the exclusive license to patents and thus a monopoly to sell…

PEPFAR, Global Fund, South Africa Must Diversify Antiretroviral Drug Suppliers

Financial Times: HIV/AIDS drugs for developing world face threat of disruption Brian Elliott, chief executive of Procela Consultants “…Fifteen generic manufacturers supply more than 95 percent of [antiretroviral drugs (ARVs)] to [low- to middle-income countries (LMICs)], of which four supply the bulk — 83 percent. … Reliance on so few…